We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $7.71M

70% more capital invested

Capital invested by funds: $87.5M → $149M (+$61.2M)

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

35% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 23

9% more funds holding

Funds holding: 91 → 99 (+8)

5.19% more ownership

Funds ownership: 29.99% → 35.18% (+5.2%)

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
1.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
31
Reduced
23
Closed
14
Calls
$13.5M
Puts
$7.71M
Net Calls
+$5.81M
Net Calls Change
+$8M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$3.4M
2
N
Nuveen
North Carolina
+$2.98M
3
Barclays
Barclays
United Kingdom
+$2.08M
4
SG Americas Securities
SG Americas Securities
New York
+$2M
5
State Street
State Street
Massachusetts
+$1.67M

Top Sellers

1
RI
RTW Investments
New York
-$4.15M
2
Deutsche Bank
Deutsche Bank
Germany
-$1.1M
3
CAC
Cowen and Company
New York
-$720K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$363K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$361K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAC
26
Cowen and Company
New York
$1.07M -$720K -216,102 -46%
DekaBank Deutsche Girozentrale
27
DekaBank Deutsche Girozentrale
Germany
$1.06M – – –
Jane Street
28
Jane Street
New York
$956K +$672K +201,526 +949%
MWNA
29
Marshall Wace North America
New York
$955K +$742K +222,739 New
Morgan Stanley
30
Morgan Stanley
New York
$950K -$235K -70,597 -24%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$910K -$132K -39,480 -16%
Charles Schwab
32
Charles Schwab
California
$899K +$76.3K +22,907 +12%
BFM
33
Boothbay Fund Management
New York
$686K +$333K +100,000 +167%
SSA
34
Schonfeld Strategic Advisors
New York
$626K +$486K +145,800 New
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$620K +$285K +85,542 +145%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$497K -$363K -108,800 -48%
KA
37
Kerrisdale Advisers
Florida
$429K +$333K +100,000 New
PVI
38
Pura Vida Investments
New York
$429K +$333K +100,000 New
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$388K +$8.48K +2,546 +3%
Walleye Trading
40
Walleye Trading
New York
$329K +$256K +76,796 New
ACA
41
Apis Capital Advisors
New York
$300K +$233K +70,000 New
Ameriprise
42
Ameriprise
Minnesota
$277K -$3.53K -1,060 -2%
SC
43
Shay Capital
New York
$257K +$200K +60,000 New
CC
44
Centiva Capital
New York
$247K +$192K +57,500 New
Deutsche Bank
45
Deutsche Bank
Germany
$198K -$1.1M -329,537 -88%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$198K -$8.87K -2,661 -5%
AIG
47
American International Group
New York
$189K +$713 +214 +0.5%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$181K -$220K -65,930 -61%
PCM
49
Prelude Capital Management
New York
$167K +$130K +39,000 New
JP Morgan Chase
50
JP Morgan Chase
New York
$161K +$9.95K +2,985 +9%
1
2
3 4 5

ABUS Hedge Fund Activity: Q3 2021 in Review

99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $149M — up 70% from $87.5M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ABUS positions and 14 closed out — a net gain of 9 holders — while 31 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.

  • 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
  • Funds reported $149M of Arbutus Biopharma stock for Q3 2021, up 70% quarter-over-quarter.
  • 23 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +9 holders.
  • The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
  • The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.

Based on aggregated 13F filings for Q3 2021.